JP2024537284A5 - - Google Patents

Info

Publication number
JP2024537284A5
JP2024537284A5 JP2024521784A JP2024521784A JP2024537284A5 JP 2024537284 A5 JP2024537284 A5 JP 2024537284A5 JP 2024521784 A JP2024521784 A JP 2024521784A JP 2024521784 A JP2024521784 A JP 2024521784A JP 2024537284 A5 JP2024537284 A5 JP 2024537284A5
Authority
JP
Japan
Application number
JP2024521784A
Other languages
Japanese (ja)
Other versions
JPWO2023064769A5 (https=
JP2024537284A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077908 external-priority patent/WO2023064769A1/en
Publication of JP2024537284A publication Critical patent/JP2024537284A/ja
Publication of JP2024537284A5 publication Critical patent/JP2024537284A5/ja
Publication of JPWO2023064769A5 publication Critical patent/JPWO2023064769A5/ja
Pending legal-status Critical Current

Links

JP2024521784A 2021-10-11 2022-10-11 抗npr1抗体を投与することにより血行動態の変化を引き起こす方法 Pending JP2024537284A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254447P 2021-10-11 2021-10-11
US63/254,447 2021-10-11
PCT/US2022/077908 WO2023064769A1 (en) 2021-10-11 2022-10-11 Methods of effecting a hemodynamic change by administering an anti-npr1 antibody

Publications (3)

Publication Number Publication Date
JP2024537284A JP2024537284A (ja) 2024-10-10
JP2024537284A5 true JP2024537284A5 (https=) 2025-12-22
JPWO2023064769A5 JPWO2023064769A5 (https=) 2025-12-22

Family

ID=84045029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521784A Pending JP2024537284A (ja) 2021-10-11 2022-10-11 抗npr1抗体を投与することにより血行動態の変化を引き起こす方法

Country Status (12)

Country Link
US (2) US20240327539A1 (https=)
EP (1) EP4415820A1 (https=)
JP (1) JP2024537284A (https=)
KR (1) KR20240099275A (https=)
CN (1) CN118159290A (https=)
AU (1) AU2022363841A1 (https=)
CA (1) CA3234238A1 (https=)
CL (1) CL2024001071A1 (https=)
CO (1) CO2024005662A2 (https=)
IL (1) IL311917A (https=)
MX (1) MX2024004302A (https=)
WO (1) WO2023064769A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313265A (en) 2021-12-06 2024-08-01 Regeneron Pharma Antagonistic antibodies against NPR1 and methods of using them
WO2024251255A1 (zh) * 2023-06-08 2024-12-12 江苏恒瑞医药股份有限公司 抗npr1抗体及其医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US9090695B2 (en) 2008-12-03 2015-07-28 Morphosys Ag Antibodies for guanylyl cyclase receptors
MY205168A (en) 2018-10-23 2024-10-04 Regeneron Pharma Anti-npr1 antibodies and uses thereof
EA202193345A1 (ru) * 2019-06-12 2022-03-16 Новартис Аг Антитела к рецептору-1 натрийуретического пептида и способы их применения
US12325752B2 (en) * 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists

Similar Documents

Publication Publication Date Title
JP2024537284A5 (https=)
CL2025003573A1 (es) Sistemas y métodos para la extracción de litio a partir de materias primas acuosas
CN307050193S (https=)
BY13167U (https=)
BY13158U (https=)
CN307049746S (https=)
CN307049691S (https=)
CN307049417S (https=)
CN307049156S (https=)
CN307049009S (https=)
CN307048860S (https=)
CN307048472S (https=)
CN307048074S (https=)
CN307047662S (https=)
CN307047366S (https=)
CN307046753S (https=)
CN307046748S (https=)
CN307046310S (https=)
CN307046232S (https=)
CN307046138S (https=)
BY13159U (https=)
CN307045761S (https=)
CN307045458S (https=)
CN307045415S (https=)
BY13160U (https=)